Esperion Therapeutics (ESPR) shares are having a very good Friday. The stock jumped more than 57% in premarket trading after the company announced it has agreed to be acquired by ARCHIMED, a healthcare investment firm, in a deal valued at roughly $1.1 billion.

Here's the headline number: Esperion shareholders will receive $3.16 per share in cash at closing. But there's also a kicker — the opportunity to participate in up to $100 million in contingent milestone payments tied to future sales performance. That's a nice sweetener for investors who have been along for the ride.

The $3.16 per share represents a 58% premium over Esperion's closing price on April 30, 2026. That's a meaningful pop, and it explains why the stock is trading at around $3.15 in premarket action. The broader markets were mixed on Thursday, but Esperion is clearly marching to its own beat today.

Esperion ended 2025 with $167.9 million in cash and equivalents, up from $144.8 million a year earlier. The company had about 245.2 million shares outstanding (excluding 2 million treasury shares). So the deal math works out to a nice premium for shareholders.

CEO Sheldon Koenig sounded optimistic about the deal: "With ARCHIMED's support, we believe Esperion will be well positioned to advance our Vision 2040 strategy and continue addressing the global burden of cardiometabolic disease." That's the kind of quote that makes you think the company sees a brighter future under new ownership.

This acquisition comes on the heels of Esperion's recent purchase of Corstasis Therapeutics Inc., a private biopharma company focused on outpatient therapies for edema related to cardiovascular, hepatic, and renal disease. So Esperion has been busy building its pipeline.

Technical Analysis

Esperion's stock has had a wild ride over the past year. It's currently trading within its 52-week range of $0.69 to $4.17. The stock sits about 4.7% below its 20-day simple moving average (SMA) and 21.8% below its 50-day SMA — that's a bearish short-term trend. But the relative strength index (RSI) is at 36.21, which is neutral, and the moving average convergence divergence (MACD) is above the signal line, hinting at a potential bullish shift. So traders are cautiously optimistic, even if the stock hasn't been able to break above those key moving averages.

Key resistance is at $2.50, a level where rallies have historically stalled. Key support sits at $1.50, where demand has tended to show up. With the buyout price at $3.16, the stock is now trading above both levels, which is a nice place to be.

Over the past 12 months, Esperion has delivered a remarkable 103.25% return, showing strong long-term momentum despite recent fluctuations. That's the kind of performance that gets investors excited.

The healthcare sector as a whole was flat on Thursday, gaining 0.00%. Esperion's premarket gain of 0.48% (before the buyout news) was already outperforming the sector by 5.21 percentage points. Over the past 30 days, the healthcare sector has declined 1.18%, but Esperion's recent gains suggest it's bucking the trend. That divergence could signal investor confidence in the company's future, especially with the acquisition news now out.

This buyout is a pivotal moment for Esperion. It provides immediate value to shareholders while positioning the company for future growth in the cardiometabolic market with ARCHIMED's backing.

Analyst Outlook

Analysts have been bullish on Esperion. The stock carries a Buy rating with an average price target of $6.33. Recent analyst moves include:

• Citizens: Market Outperform (raised target to $5.00) on March 13
• Needham: Buy (raised target to $5.00) on March 3
• Piper Sandler: Initiated with Overweight (target $9.00) on November 25, 2025

Those targets are now largely moot given the buyout, but they show that Wall Street saw value in Esperion before the deal was announced.

ESPR Price Action: Esperion shares were up 57.50% at $3.15 in premarket trading on Friday. Over the past month, ESPR has gained about 13.7% versus a 9.9% rise in the S&P 500. Year-to-date, the stock is down roughly 18% compared to the index's 4.8% gain. But with the buyout, those year-to-date losses are now a distant memory for shareholders who held on.